Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYT-200 · 2 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| LYT-200 | DRUG | monoclonal antibody (mAb), targeting galectin-9 protein |
| Tislelizumab | DRUG | anti-PD-1 monoclonal antibody |
| Gemcitabine/nab-paclitaxel | DRUG | chemotherapy |
| Venetoclax | DRUG | Bcl-2 inhibitor |
| Azacitidine | DRUG | Hypomethylating agent |
| Decitabine | DRUG | Hypomethylating agent |
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LYT-200 is an investigational small molecule being studied for the treatment of adult recurrent acute myeloid leukemia (AML) and relapsed or refractory, high-risk myelodysplastic syndrome (MDS). It is also being evaluated in patients with locally advanced or metastatic solid tumors, including pancreatic cancer, urothelial carcinoma, head and neck cancer, and colorectal cancer.
LYT-200 is being developed by PureTech Health plc, a biopharmaceutical company listed on the London Stock Exchange under the ticker PRTC. The company is conducting clinical trials to evaluate the safety and efficacy of LYT-200 in patients with certain hematologic malignancies and solid tumors.
LYT-200 is currently in Phase 1 clinical development. One Phase 1 trial is recruiting patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, while a separate Phase 1/Phase 2 study in solid tumors has been completed. LYT-200 remains investigational and has not been approved by regulatory authorities.
LYT-200 is being studied in two clinical trials. NCT05829226 is a Phase 1 study in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, currently recruiting with a target enrollment of 90. NCT04666688 is a completed Phase 1/Phase 2 study of LYT-200 alone or with chemotherapy or tislelizumab in solid tumors.
No, LYT-200 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. The available data show that LYT-200 is still in clinical development and has not received marketing approval from the U.S. Food and Drug Administration or any other regulatory agency.